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in 1 patient due to predicted long duration of 
the procedure. Three TEE views: 0o lower ‑mid‑
‑esophageal, 120o upper ‑mid ‑esophageal, and 
transgastric were selected for visualization of 
the right ventricle (RV) and were further inves‑
tigated. Similar to other studies,6 the useful‑
ness of particular TEE views was evaluated with 
a self ‑developed 3‑grade score (TABLE 1). Addition‑
ally, the angle between the long axis of the Mi‑
cra device and the long axis of the interventric‑
ular septum, herein termed “deployment angle,” 
was evaluated on TEE. All patients underwent 
transthoracic echocardiography, chest radiogra‑
phy, and device interrogation on the postproce‑
dural day. The clinical course as well as the elec‑
trical parameters of the Micra TPS were evaluat‑
ed during follow ‑up visits.
The study was conducted according to the Dec‑
laration of Helsinki and was approved by the Bio‑
ethical Committee of the Medical University of 
Lodz (Łódź, Poland). Each patient gave written 
informed consent before undergoing the im‑
plantation procedure.
Statistical analysis Statistical analysis was per‑
formed using the Statistica software (StatSoft 
Inc., Tulsa, Oklahoma, United States). The t test or 
Mann–Whitney test was used for between ‑group 
comparisons of continuous variables according to 
data distribution. The χ2 test and its modification 
were used to compare categorical data. A P val‑
ue of less than 0.05 was considered significant.
Results and discussion The study group in‑
cluded 15 men (63%) and 9 women (mean [SD] 
Introduction Clinical experience with leadless 
pacemakers is still limited, and safety issues re‑
main an important concern for clinicians. Sep‑
tal positioning of a leadless pacemaker might 
be safer in terms of reducing the risk of heart 
wall perforation.1‑3
Fluoroscopic guidance is routinely used for im‑
plantation of conventional pacemakers. It is also 
used for leadless pacing systems; however, its in‑
adequacy in the precise positioning of leads has 
been reported.4 Transesophageal echocardiog‑
raphy (TEE) has an established value in guid‑
ing several procedures in invasive cardiology.5 
Therefore, we aimed to determine the useful‑
ness of this technique in guiding septal implan‑
tation of the Micra transcatheter pacing system 
(TPS) (Medtronic, Minneapolis, United States).
Methods This single ‑center prospective ob‑
servational study included the first 24 consecu‑
tive patients who underwent an implantation of 
the Micra TPS. The septal position of the pace‑
maker was considered optimal to reduce the risk 
of heart perforation. Fluoroscopic guidance 
with contrast media injection was used accord‑
ing to the standard of care in our center, includ‑
ing single ‑plane fluoroscopy in at least 3 com‑
plementary projections. Subsequently, in all pa‑
tients, the septal positioning of the Micra de‑
vice achieved with fluoroscopy was confirmed 
with intraprocedural TEE (Vivid 9, GE Health‑
care, Salem, Connecticut, United States). Local 
anesthesia together with intravenous conscious 
sedation (midazolam and fentanyl) was used 
in 23 patients. General anesthesia was applied 
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appeared to be on the free wall of the RV. Sub‑
sequently, the device was relocated to the inter‑
ventricular septum. In these cases, nonseptal po‑
sition of the device was characterized by a more 
acute deployment angle (mean [SD], 18.8o [6.4o]
vs 27.0o [8.4o]; P <0.01).
The mean (SD) duration of implantations 
was 74.6 (34.9) minutes, with a mean (SD) re‑
quired duration of fluoroscopy of 7.9 (5.2) min‑
utes. The procedures resulted in optimal electri‑
cal parameters in all cases (mean [SD] capture 
threshold, 0.51 [0.23] V; sensing, 11.5 [4.8] mV; 
and impedance, 703 [140] ohm). Although we did 
not observe any anatomical signs of nonoptimal 
TEE ‑guided septal TPS deployment, in 9 patients 
(37.2%), the device had to be repositioned at least 
once to achieve optimal electrical parameters. 
The rate of repositions was similar to that re‑
ported by other authors.7,8
Periprocedural complications were not ob‑
served. In all patients, intraprocedural and in‑
‑hospital electrical parameters of the pacing sys‑
tem were within the normal range. In ‑hospital 
observation was uneventful in all patients. Dur‑
ing the mean (SD) follow ‑up of 418 (224) days, 
1 patient died of noncardiovascular cause and an‑
other one developed gradual elevation of pacing 
threshold that did not require an intervention.
The first ‑in ‑human experience with leadless 
pacemakers was reported in 2014, summarizing 
implantations of these devices in 33 patients.9 
In that study, 1 patient had cardiac tamponade 
that resulted in death despite a successful chest 
surgery. Subsequent studies described low rates 
of pericardial effusion or tamponade (observed 
in 1% to 2% of cases).7,10 Nevertheless, some au‑
thors reported a higher prevalence of this com‑
plication.2,3,11 The septal positioning of the Mi‑
cra device was suggested to have a favorable ef‑
fect on the risk of perforation.7,8 However, in all 
relevant studies, devices were implanted main‑
ly into the RV apex.2,7,10,12 Suprisingly, in 4 of the 
5 patients with Micra ‑related pericardial effu‑
sion or tamponade, the devices were implant‑
ed in the septal position.12 In a study by Kacz‑
marek et al,3 who investigated septal implanta‑
tions of Micra devices, a single heart perforation 
occurred when a delivery sheath was directed to 
the free wall of the RV.3 
The above examples as well as the experience 
with conventional pacemakers suggest that flu‑
oroscopy might be insufficient for guiding a pre‑
cise lead or device implantation in the interven‑
tricular septum, at least in some cases. Therefore, 
in these cases, an additional use of echocardiog‑
raphy seems to be advisable.4,13 In our experience, 
the upper ‑mid ‑esophageal position of the TEE 
probe appeared to be the best option for most 
patients. Similar views are used for other car‑
diovascular interventions within the interven‑
tricular septum.14 According to our results, 3‑di‑
mensional imaging facility offers no advantage 
age, 69.7 [18] years; range, 29–95 years). Stable 
coronary artery disease was reported in 29% of 
patients. Two patients had reduced left ventric‑
ular ejection fraction and were diagnosed with 
congestive heart failure. Approximately half 
of the study group (54.2%) presented with chron‑
ic renal failure. Atrioventricular blocks with si‑
nus rhythm were found to be the most com‑
mon indication for permanent pacing (58.3%), 
followed by bradycardia associated with chron‑
ic atrial tachyarrhythmia (29.2%) and by si‑
nus node dysfunction (12.5%). None of the pa‑
tients in sinus rhythm developed pacemaker 
syndrome after implantation. The main reason 
for the selection of a leadless system, reported 
in 22 individuals (91.8%), was an increased risk 
of infection related to conventional pacemak‑
ers, which resulted from chronic hemodialysis 
(41.6%), history of previous device ‑related infec‑
tion (33.3%), chronic infections (20.8%), or long‑
‑term high ‑dose steroid therapy (8.3%).
Transesophageal echocardiography imag‑
es appropriate for guidance of the device po‑
sitioning were obtained in all patients. Mid‑
‑esophageal probe positions, especially upper‑
‑mid ‑esophageal, were more useful than the 
transgastric one, and a 3‑dimensional (3D) im‑
aging facility did not provide any additional ben‑
efit. For the lower ‑mid ‑esophageal projection, 
the mean (SD) score was 1.4 (0.7) for 2‑dimen‑
sional (2D) imaging, as compared with 0.8 (0.5) 
for 3D imaging (P <0.01). For the upper ‑mid‑
‑esophageal projection, the mean (SD) score for 
2D and 3D imaging was 1.8 (0.4) and 0.9 (0.5), 
respectively (P <0.01). Finally, for the transgas‑
tric projection, the mean (SD) score for 2D and 
3D imaging was 0.8 (0.7) and 0.2 (0.4), respec‑
tively (P <0.01).
The septal position (50% mid and 50% low 
septum) of the device was achieved in all 24 pa‑
tients. Transesophageal echocardiography al‑
lowed a verification of the device positioning 
in 10 cases (41.6%), in which the initial septal 
position selected based on fluoroscopy actually 
TABLE 1 Transesophageal echocardiography scoring
TEE projection Score 0 Score 1 Score 2 P value
TEE ‑LME‑0o 2 11 11 <0.01a
<0.01bTEE ‑UME‑120o 0 5 19
TEE ‑TG 10 10 4
a For the χ2 for the 3×3 table
b For the χ2 for the 3×2 table (score 2 vs <2)
Scoring system: 0, images that did not visualize the Micra device and therefore could not be used 
to support the procedure; 1, images of moderate quality that visualized the device but not precisely 
enough to guide implantation; 2, the Micra device visualized in detail in relation to the free wall 
of the right ventricle and interventricular septum
Abbreviations: LME, lower ‑mid ‑esophageal; TEE, transesophageal echocardiography; TG, 
transgastric; UME, upper ‑mid ‑esophageal
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over standard 2‑dimentional imaging. This is in 
line with a report by Faletra et al,14 and it prob‑
ably results from a higher number of artifacts 
in the case of the 3D technique.
Our main finding is that the septal position‑
ing of the Micra device can be misdiagnosed in 
40% of patients. Therefore, we recommend using 
TEE on top of fluoroscopy when planning sep‑
tal implantation of the device. The main limi‑
tation of our study is the lack of randomiza‑
tion and a relatively small number of patients. 
Therefore, our findings should be confirmed in 
larger studies.
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